Q1 2026 Allogene Therapeutics Inc Earnings Call Transcript
Key Points
- Allogene Therapeutics Inc (ALLO) reported promising interim results from its Alpha-3 trial, with a 58.3% MRD clearance rate in the Semicell arm compared to 16.7% in the observation arm.
- The company observed a favorable safety profile in the Alpha-3 trial, with no CRS, ICANS, or treatment-related hospitalizations, allowing for outpatient management.
- Allogene Therapeutics Inc (ALLO) has expanded its global reach with regulatory approvals in Australia and South Korea, increasing the study footprint to over 80 sites worldwide.
- The company strengthened its financial position with a public offering that generated approximately $200.4 million, extending its cash runway into the first quarter of 2029.
- The LO-329 program in autoimmune indications is progressing well, with early signs of clinical activity and favorable tolerability observed in initial dosing cohorts.
- The Alpha-3 trial is still in early stages, and the interim results, while promising, are preliminary and need further validation through EFS analysis.
- The LO-329 program is in early clinical development, and the initial doses are lower than those explored in other CAR-T approaches, which may delay the observation of significant clinical outcomes.
- Allogene Therapeutics Inc (ALLO) reported a net loss of $42.6 million for the first quarter, reflecting continued investment in clinical programs.
- The company increased its guidance for operating cash expenses in 2026 from approximately $150 million to $165 million, indicating higher than anticipated costs.
- There is competition in the autoimmune CAR-T space, which could impact the enrollment and progress of the LO-329 resolution study.
Hello.
Thank you for standing by, and welcome to Allotene Therapeutics' first quarter 2026 conference call. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press *11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press *11. Everyone again. Please be aware that today's conference call is being recorded. I would now like to turn the call over to Christine Casiano, Chief Corporate Affairs and Brand Strategy Officer. Ms. Casiano, please go ahead.
Thank you, operator, and welcome everyone to Allergen's conference call. After the market closed, Allergen issued a press release that provided a business update and financial results for the first quarter of 2026. This press release and today's webcast are available on our website.
Following our prepared remarks, we will
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
